These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 27872331)

  • 21. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
    Choi MR; Jiles C; Seibel NL
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):e268-71. PubMed ID: 20736848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential cross-reactivity of polysorbate 80 and cremophor: A case report.
    Bibera MAT; Lo KMK; Steele A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1279-1281. PubMed ID: 31955702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF].
    Uchiyama K; Yamada M; Shiiba Y; Kasazaki S; Suga K; Iwabuchi H; Asoda S; Uehara K
    Gan To Kagaku Ryoho; 2017 Jul; 44(7):585-589. PubMed ID: 28790262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaphylactic reaction and unrelated, subsequent, known side effects during therapy with thiethylperazine.
    Rossetti G; Livio F; Roulet E; Hofer MF
    Pediatr Allergy Immunol; 2005 Aug; 16(5):453-5. PubMed ID: 16101941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In brief: Severe hypersensitivity reactions with rolapitant IV emulsion (Varubi).
    Med Lett Drugs Ther; 2018 Jan; 60(1539):24. PubMed ID: 29431950
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas.
    Tsukahara K; Nakamura K; Motohashi R; Sato H; Endo M; Katsube Y; Ueda Y; Suzuki M
    Acta Otolaryngol; 2014 Nov; 134(11):1198-204. PubMed ID: 25315920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypersensitivity and idiosyncratic reactions to oxaliplatin.
    Thomas RR; Quinn MG; Schuler B; Grem JL
    Cancer; 2003 May; 97(9):2301-7. PubMed ID: 12712487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
    Schnadig ID; Agajanian R; Dakhil C; Gabrail NY; Smith RE; Taylor C; Wilks ST; Schwartzberg LS; Cooper W; Mosier MC; Payne JY; Klepper MJ; Vacirca JL
    Future Oncol; 2016 Jun; 12(12):1469-81. PubMed ID: 26997579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
    Ruhlmann CH; Christensen TB; Dohn LH; Paludan M; Rønnengart E; Halekoh U; Hilpert F; Feyer P; Kristensen G; Hansen O; Keefe D; Herrstedt J
    Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.
    Hopps S; Medina P; Pant S; Webb R; Moorman M; Borders E
    J Oncol Pharm Pract; 2013 Sep; 19(3):222-7. PubMed ID: 23135806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM; Lenz KL
    Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypersensitivity reactions to oxaliplatin in two asian patients.
    Ng CV
    Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.
    Craig TJ; Li HH; Riedl M; Bernstein JA; Lumry WR; MacGinnitie AJ; Stolz LE; Biedenkapp J; Chyung Y
    J Allergy Clin Immunol Pract; 2015; 3(2):206-212.e4. PubMed ID: 25609335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital.
    Keating K; Walko C; Stephenson B; O'Neil BH; Weiss J
    J Oncol Pharm Pract; 2014 Dec; 20(6):409-16. PubMed ID: 24243920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.